Trial Profile
A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-394
- Sponsors Merck Sharp & Dohme
- 05 Jul 2023 Planned End Date changed from 30 Jun 2023 to 31 Oct 2024.
- 06 Jun 2023 Results of post hoc analysis assessing Landmark analysis of OS by response status in previously treated patients (pts) with advanced hepatocellular carcinoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 01 Dec 2022 Results assessing safety and efficacy of Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma published in the Journal of Clinical Oncology